124 related articles for article (PubMed ID: 11028837)
1. Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists--preliminary results.
Späth M; Welzel D; Färber L
Scand J Rheumatol Suppl; 2000; 113():72-7. PubMed ID: 11028837
[TBL] [Abstract][Full Text] [Related]
2. The effect of granisetron, a 5-HT3 receptor antagonist, in the treatment of chronic fatigue syndrome patients--a pilot study.
The GK; Prins J; Bleijenberg G; van der Meer JW
Neth J Med; 2003 Sep; 61(9):285-9. PubMed ID: 14692441
[TBL] [Abstract][Full Text] [Related]
3. Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients.
Färber L; Stratz TH; Brückle W; Späth M; Pongratz D; Lautenschläger J; Kötter I; Zöller B; Peter HH; Neeck G; Welzel D; Müller W;
Int J Clin Pharmacol Res; 2001; 21(1):1-13. PubMed ID: 11708570
[TBL] [Abstract][Full Text] [Related]
4. The effect of ondansetron, a 5-HT3 receptor antagonist, in chronic fatigue syndrome: a randomized controlled trial.
The GK; Bleijenberg G; Buitelaar JK; van der Meer JW
J Clin Psychiatry; 2010 May; 71(5):528-33. PubMed ID: 20122367
[TBL] [Abstract][Full Text] [Related]
5. Antipruritic effects of two different 5-HT3 receptor antagonists and an antihistamine in haemodialysis patients.
Weisshaar E; Dunker N; Röhl FW; Gollnick H
Exp Dermatol; 2004 May; 13(5):298-304. PubMed ID: 15140020
[TBL] [Abstract][Full Text] [Related]
6. The use of the 5-HT3-receptor antagonist ondansetron for the treatment of postcardiotomy delirium.
Bayindir O; Akpinar B; Can E; Güden M; Sönmez B; Demiroğlu C
J Cardiothorac Vasc Anesth; 2000 Jun; 14(3):288-92. PubMed ID: 10890483
[TBL] [Abstract][Full Text] [Related]
7. Fibromyalgia treatment with intravenous tropisetron administration.
Stratz T; Färber L; Varga B; Baumgartner C; Haus U; Müller W
Drugs Exp Clin Res; 2001; 27(3):113-8. PubMed ID: 11447769
[TBL] [Abstract][Full Text] [Related]
8. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
9. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue.
Theal JJ; Toosi MN; Girlan L; Heslegrave RJ; Huet PM; Burak KW; Swain M; Tomlinson GA; Heathcote EJ
Hepatology; 2005 Jun; 41(6):1305-12. PubMed ID: 15915460
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia.
Späth M; Stratz T; Neeck G; Kötter I; Hammel B; Amberger CC; Haus U; Färber L; Pongratz D; Müller W
Scand J Rheumatol; 2004; 33(4):267-70. PubMed ID: 15370724
[TBL] [Abstract][Full Text] [Related]
11. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost.
Abali H; Celik I
Cancer Invest; 2007; 25(3):135-9. PubMed ID: 17530482
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative nausea and vomiting after craniotomy: a meta-analysis.
Neufeld SM; Newburn-Cook CV
J Neurosurg Anesthesiol; 2007 Jan; 19(1):10-7. PubMed ID: 17198095
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group.
Färber L; Stratz T; Brückle W; Späth M; Pongratz D; Lautenschläger J; Kötter I; Zöller B; Peter HH; Neeck G; Alten R; Müller W
Scand J Rheumatol Suppl; 2000; 113():49-54. PubMed ID: 11028832
[TBL] [Abstract][Full Text] [Related]
14. Tropisetron vs ondansetron for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomized double-blind, placebo-controlled study.
Argiriadou H; Papaziogas B; Pavlidis T; Parlapani A; Georgiou M; Papagiannopoulou P; Papaziogas T
Surg Endosc; 2002 Jul; 16(7):1087-90. PubMed ID: 12165828
[TBL] [Abstract][Full Text] [Related]
15. Intra-articular treatment of arthritides and activated osteoarthritis with the 5-HT3 receptor antagonist tropisetron. A double-blind study compared with methylprednisolone.
Samborski W; Stratz T; Mackiewicz S; Müller W
Scand J Rheumatol Suppl; 2004; 119():51-4. PubMed ID: 15515415
[TBL] [Abstract][Full Text] [Related]
16. The 5-HT3 blockers in the treatment of the primary fibromyalgia syndrome: a 10-day open study with Tropisetron at a low dose.
Samborski W; Stratz T; Lacki JK; Klama K; Mennet P; Müller W
Mater Med Pol; 1996; 28(1):17-9. PubMed ID: 9088121
[TBL] [Abstract][Full Text] [Related]
17. A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome.
McDermott C; Richards SC; Thomas PW; Montgomery J; Lewith G
QJM; 2006 Jul; 99(7):461-8. PubMed ID: 16809351
[TBL] [Abstract][Full Text] [Related]
18. Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis.
Monaca-Charley C; Stojkovic T; Duhamel A; De Seze J; Ferriby D; Vermersch P
J Neurol; 2003 Oct; 250(10):1190-4. PubMed ID: 14586600
[TBL] [Abstract][Full Text] [Related]
19. Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder.
Amsterdam JD; Shults J; Rutherford N
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):100-6. PubMed ID: 17804135
[TBL] [Abstract][Full Text] [Related]
20. Personal view: a potential novel treatment for fatigue complicating chronic liver disease--how should its efficacy be evaluated?
Jones EA
Aliment Pharmacol Ther; 2006 Apr; 23(8):1113-6. PubMed ID: 16611271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
